Core Alternative Capital’s AbbVie ABBV Stock Holding History

Core Alternative Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$749K	Buy	2,976 +464	+18%	+$99.8K	0.22%	75
2026 Q1	$546K	Buy	2,512 +357	+17%	+$79.2K	0.16%	78
2025 Q4	$492K	Buy	2,155 +1,872	+661%	+$426K	0.14%	77
2025 Q3	$65.5K	Buy	283 +3	+1%	+$611	0.02%	113
2025 Q2	$52K	Sell	280 -2,772	-91%	-$515K	0.01%	123
2025 Q1	$639K	Sell	3,052 -82	-3%	-$15.9K	0.15%	78
2024 Q4	$557K	Sell	3,134 -803	-20%	-$148K	0.12%	83
2024 Q3	$777K	Buy	3,937 +150	+4%	+$28K	0.15%	74
2024 Q2	$650K	Sell	3,787 -8	-0.2%	-$1.32K	0.13%	78
2024 Q1	$691K	Sell	3,795 -772	-17%	-$133K	0.12%	75
2023 Q4	$708K	Sell	4,567 -1,018	-18%	-$148K	0.12%	75
2023 Q3	$833K	Buy	5,585 +2,988	+115%	+$439K	0.13%	76
2023 Q2	$350K	Buy	2,597 +176	+7%	+$25.8K	0.05%	81
2023 Q1	$386K	Buy	2,421 +90	+4%	+$13.8K	0.05%	77
2022 Q4	$377K	Sell	2,331 -401	-15%	-$61.5K	0.05%	86
2022 Q3	$367K	Sell	2,732 -156	-5%	-$22.4K	0.06%	81
2022 Q2	$442K	Buy	2,888 +1,080	+60%	+$165K	0.1%	88
2022 Q1	$293K	Buy	1,808 +1,490	+469%	+$216K	0.08%	90
2021 Q4	$43K	Buy	318 +60	+23%	+$7.09K	0.01%	122
2021 Q3	$28K	Buy	+258	New	+$29.5K	0.01%	83

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Core Alternative Capital's ABBV Position: Q2 2026 in Review

Core Alternative Capital increased its AbbVie (ABBV) stake by 18% in Q2 2026, buying an estimated $99.8K and bringing the position to 2,976 shares worth $749K. The position accounts for 0.22% of the portfolio, ranked #75.

Core Alternative Capital first reported a position in ABBV in Q3 2021 and has held it in 20 quarters since. The position peaked at $833K in Q3 2023. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Core Alternative Capital held 2,976 shares of AbbVie worth $749K as of Q2 2026.
Core Alternative Capital bought 464 AbbVie shares in Q2 2026, an estimated $99.8K.
AbbVie made up 0.22% of Core Alternative Capital's portfolio in Q2 2026, its #75 holding.
Core Alternative Capital first reported a position in AbbVie in Q3 2021 and has held it in 20 quarters since.
Core Alternative Capital's AbbVie position peaked at $833K in Q3 2023.
4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Core Alternative Capital's 13F filing for Q2 2026, filed 14 Aug 2026.